Back to Search Start Over

Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis

Authors :
Nora Chouha
Hussein Abou-Hamdan
Hajime Yurugi
Riku Yoshii
Hiromi Ii
Ahmad Najem
Ghanem E. Ghanem
Susumu Nakata
Krishnaraj Rajalingam
Yu Peng
Dong Wang
Canan G. Nebigil
Laurent Désaubry
Nanomédecine Régénérative (NanoRegMed)
Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre de Recherche en Biomédecine de Strasbourg (CRBS)
Laboratoire de Chimie et Chimie de l'Environnement (LCCE)
Université Hadj Lakhdar Batna 1
University Medical Center [Mainz]
Kyoto University
Institut Jules Bordet [Bruxelles]
Faculté de Médecine [Bruxelles] (ULB)
Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)
Université libre de Bruxelles (ULB)
Tianjin University of Science and Technology (TUST)
Xinjiang University
univOAK, Archive ouverte
Source :
European Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, 2022, 242, pp.114635. ⟨10.1016/j.ejmech.2022.114635⟩
Publication Year :
2022
Publisher :
HAL CCSD, 2022.

Abstract

Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melanocytes, fluorizoline also induces the synthesis of melanin. Herein we report the first structural requirement of fluorizoline analogues for these activities. We identified in particular some compounds that display enhanced anti-C-RAF and anti-MEK activities, and a higher cytotoxicity in HeLa cells compared to fluorizoline. These results provide a foundation for further optimization of PHB ligands for the treatment of cancers. We also discovered an analogue of fluorizoline that displays pharmacological effects opposed to those of fluorizoline and that can be used as a chemical tool to explore PHB signaling in cancers and other diseases.

Details

Language :
English
ISSN :
02235234 and 17683254
Database :
OpenAIRE
Journal :
European Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, 2022, 242, pp.114635. ⟨10.1016/j.ejmech.2022.114635⟩
Accession number :
edsair.doi.dedup.....4cc9b51a7fa505ea1d0e6306f4d0fe36
Full Text :
https://doi.org/10.1016/j.ejmech.2022.114635⟩